Adam Feuerstein Does Not Think AMAG Pharma Will Be Sold Until After Phase 3 Data
Adam Feuerstein, Senior Biotech Columnist at TheStreet.com, tweeted this morning that he believes AMAG Pharmaceuticals (NASDAQ: AMAG) will eventually be sold, but not before the release of its phase 3 data in a couple months.
AMAG Pharmaceuticals announced this morning that it has hired Jefferies & Company as a strategic advisor. Shares of AMAG Pharma are currently trading up over 4% .
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.